

North Central Cancer Treatment Group

N057K: Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ)
Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma

Addendum 3 – January 30, 2009

Summary

- Administrative/editorial changes.

Replacement pages are included. Please incorporate into the protocol and keep this addendum with your protocol.

Title page Updated to reflect the addition of Addendum 3 and revised NCI version date.

Section 14.0 **Body Fluid Biospecimens**
Pages 44-45: The title of the NCCTG Research Blood Specimen Form has been revised in Sections 14.261 and 14-272 as follows:
NCCTG Research Blood ~~Specimen~~ **Requisition** Form

Section 18.0 **Records and Data Collection Procedures**
Page 66: The **Folstein Mini Mental State Form** was inadvertently omitted from the table and has now been added as reflected in the fifth row.